Basic Product Information
| Product name | tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate |
| Synonym | 1-BOC-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE; 4-(6-Aminopyridin-3-yl)piperazine-1-carboxylicacidtert-butylester; 1-Piperazinecarboxylicacid,4-(6-aMino-3-pyridinyl)-,1,1-diMethylethylester; tert-butyl4-(6-aMinopyri;4-(6-aMinopyridin-3-yl)piperazine-1-carboxylic; PALBOCICLIB4; 2-Methyl-2-propanyl4-(6-amino-3-pyridinyl)-1-piperazinecarboxylate |
| CAS NO. | 571188-59-5 |
| Appearance | Light yellow to brown color powder |
| Purity | 99% Min |
| MF | C14H22N4O2 |
| MW | 278.35 |
| Structural formula |  |
| Related categories | Pharmaceutical intermediates |
| Transport Information | Non-hazardous materials |
| HS Code | 2933599099 |
| Product Manager Email | sophia@coreychem.com |
Application
This compound is a Boc-protected piperazine-pyridine pharmaceutical intermediate, primarily used in the synthesis of CDK4/6 inhibitor-based antitumor drugs, and also serves as a versatile intermediate for organic synthesis and new drug R&D.
I. Core Pharmaceutical Applications (Primary Use)
Key Intermediate for Palbociclib
It is a core building block for CDK4/6 inhibitors (Cyclin-Dependent Kinase 4/6 inhibitors), such as Palbociclib (a targeted therapy for breast cancer). It provides the pyridine-piperazine core structure fragment and is essential for the industrial production of this API.
The Boc (tert-butoxycarbonyl) protecting group can be gently removed in later synthesis steps, ensuring selectivity in subsequent coupling and cyclization reactions, reducing impurities, and guaranteeing API purity and efficacy.
Intermediate for Other CDK4/6 Inhibitors
It can be used for structural modification and synthesis of other CDK4/6 inhibitors, including Ribociclib and Abemaciclib, adapting to the molecular framework construction of similar kinase inhibitors.
R&D of Kinase Inhibitor Drugs
With its pyridine-piperazine heterocyclic structure, it acts as a general synthetic building block for other kinase inhibitors (e.g., JAK, FLT3, EGFR), used in laboratory R&D and process optimization for antitumor, anti-inflammatory, and immunomodulatory drugs.
II. General Organic Synthesis Applications
Building Block for Nitrogen-Containing Heterocyclic Compounds
The molecule contains three reactive sites: 6-aminopyridine, piperazine, and Boc protecting group. It can construct various nitrogen-containing heterocyclic drug molecules through deprotection, nucleophilic substitution, condensation, and cyclization, supporting the structural diversification of small-molecule drugs.
Structural Modification of Drug Molecules
As a linker/side-chain fragment, it is introduced into drug molecules to enhance target binding affinity, water solubility, or metabolic stability, widely used in structural optimization of antitumor, anti-infective, and neurological drugs.
III. Application Characteristics and Positioning
It is a high-purity pharmaceutical intermediate, mainly supplied to API manufacturers and CRO/CDMO companies. It is not used directly as a formulation or API, but requires multi-step synthesis to be converted into final drugs.
Its core value lies in providing the key structural unit for CDK4/6 inhibitors, supporting the industrial production and R&D of targeted therapies for malignant tumors such as breast cancer.
Contact information:
Contact: Sophia Li
Email: sophia@coreychem.com
